載入中
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
一般交易時段
US$20.26
−US$0.24 · -1.17%
盤中時間採用ET。市場資料可能有所延遲。
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
日內區間
目前US$20.26
52週區間
目前US$20.26
盤中時間採用ET。市場資料可能有所延遲。
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
日內區間
目前US$20.26
52週區間
目前US$20.26
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1679.5萬 USD | — | — | — | — |
| 銷貨成本 | 936.5萬 USD | — | — | — | — |
| 毛利 | 743萬 USD | — | — | — | — |
| 研究與開發 | 122.8萬 USD | 117.94萬 USD | 257.94萬 USD | 39.17萬 USD | 20.9萬 USD |
| 銷售、一般及管理費用 | 3707.6萬 USD | 639.2萬 USD | 428.29萬 USD | 192.64萬 USD | 62.99萬 USD |
| 營業費用 | 3986萬 USD | 757.14萬 USD | 686.23萬 USD | 231.82萬 USD | 83.9萬 USD |
| 利息收入 | 5000 USD | — | — | — | — |
| 利息支出 | 301.2萬 USD | 78.64萬 USD | 51.85萬 USD | 14.04萬 USD | 253 USD |
| 折舊和攤銷 | 228.5萬 USD | — | — | — | — |
| 營業利益 | −3243萬 USD | −757.14萬 USD | −686.23萬 USD | −231.82萬 USD | −83.9萬 USD |
| 淨利 | −4331.9萬 USD | −795.53萬 USD | −738.08萬 USD | −245.86萬 USD | −59.54萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$49.67
上漲空間 145.16%評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年7月2日 | 1:10 | — | — |
已生效 2025年7月2日
1:10
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
